Bharat Parenterals touches roof as its arm receives EIR from USFDA for Vadodara manufacturing facility
Bharat Parenterals is locked its upper circuit at Rs. 1667.20, up by 79.35 points or 5.00% from its previous closing of Rs. 1587.85 on the BSE.
The scrip opened at Rs. 1526.00 and has touched a high and low of Rs. 1667.20 and Rs. 1525.50 respectively. So far 2251 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 1870.00 on 02-Dec-2024 and a 52 week low of Rs. 802.00 on 04-Mar-2025.
Last one week high and low of the scrip stood at Rs. 1667.20 and Rs. 1525.50 respectively. The current market cap of the company is Rs. 1137.17 crore.
The promoters holding in the company stood at 67.19%, while Institutions and Non-Institutions held 0.65% and 32.16% respectively.
Bharat Parenterals’ subsidiary -- Innoxel Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its finished dosage manufacturing facility in Vadodara, Gujarat.
This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids. With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection. This milestone reinforces Innoxel’s commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
